TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependenceGongwei Wu, Myles Brown, Noriaki Yoshida et al.|Science Translational Medicine|2023Cited by 13
Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell LymphomaAlison J. Moskowitz, Sarah McCue Horwitz, Lisa Sarmasti et al.|Blood|2024Cited by 10
Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaBeatriz Wills, Alison J. Moskowitz, Nivetha Ganesan et al.|Blood|2022Cited by 0